A clinical and immunohistochemical study on gastrointestinal mesenchymal tumor (GIMT): RCAS1 as a predictor for recurrence of GIMT.
A clinical and immunohistochemical study on gastrointestinal mesenchymal tumor (GIMT): RCAS1 as a predictor for recurrence of GIMT.
复制标题
胃肠道间质肿瘤 (GIMT) 的临床和免疫组织化学研究：RCAS1 作为 GIMT 复发的预测因子。
DOI：
10.3892/or.14.5.1127
复制
发表时间：
2005
期刊：
影响因子：
4.2
通讯作者：
Y. Nakajima
中科院分区：
文献类型：
--
作者：
A. Naito;M. Narikiyo;Yukishige Yamada;M. Ueno;K. Kamada;T. Hachisuka;R. Yoriki;T. Mizuno;Y. Nakajima
胃肠道间质肿瘤（GIMT）是胃肠道最常见的间质肿瘤。RCAS 1（SiSo细胞上表达的受体结合癌抗原）是一种癌细胞表面抗原，已被鉴定为几种癌症类型的预后因子。据认为，肿瘤细胞通过表达RCAS 1来逃避免疫攻击，RCAS 1诱导受体阳性免疫细胞的凋亡。目前的研究旨在阐明这些肿瘤的组织发生，通过使用各种免疫组化标记，并确定参数，这将有助于建立恶性的标准，在GIMT。我们还讨论了RCAS 1的表达在GIMT的诊断和预后的临床病理意义。共审查了70例GIMT。免疫组织化学进行了1990年和2000年之间，与抗生物素蛋白-生物素-过氧化物酶复合物的方法上3微米厚的部分福尔马林固定石蜡包埋标本的GIMT。使用针对以下抗原的抗体：KIT（CD 117）、CD 34 α-SMA、结蛋白、细胞角蛋白、S-100蛋白、p53和RCAS 1。使用Stat View-J 5.0统计软件包进行无复发生存分析。无复发预后的单变量分析表明，p53表达（p=0.0333）和RCAS 1表达（p=0.0008）的抗体检测与显著较高的复发潜力相关。在多变量分析中，肿瘤大小和RCAS 1表达与无复发生存率独立负相关。RCAS 1在GIMT中的表达以前没有报道过;事实上，我们的研究表明RCAS 1的表达不仅与癌的复发相关，而且与间叶肿瘤的复发相关。
Gastrointestinal mesenchymal tumors (GIMTs) are the most common mesenchymal tumors of the gastrointestinal tract. RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a cancer cell-surface antigen and has been identified as a prognostic factor in several cancer types. It is thought that tumor cells escape immune attack by expressing RCAS1, which induces apoptosis in receptor-positive immune cells. The current study was designed to elucidate the histogenesis of these tumors by using various immunohistochemical markers, and identify parameters that will help to establish the criteria of malignancy in the GIMT. We also discuss the clinicopathological significance of RCAS1 expression in the diagnosis and prognosis of GIMTs. A total of 70 cases of GIMTs were reviewed. Immunohistochemistry was performed between 1990 and 2000, with the avidin-biotin-peroxidase complex method on 3 microm-thick sections of formalin-fixed paraffin-embedded specimens of GIMTs. Antibodies to the following antigens were used: KIT (CD117), CD34 alpha-SMA, Desmin, cytokeratin, S-100 protein, p53, and RCAS1. Recurrence-free survival analysis was done with Stat View-J 5.0 statistical packages. Univariate analysis for a recurrence-free prognosis demonstrated that antibody detection of p53 expression (p=0.0333) and expression of RCAS1 (p=0.0008) is correlated with a significantly higher potential of recurrence. On multivariate analysis, tumor size and RCAS1 expression were independently and inversely correlated with recurrence-free survival. The expression of RCAS1 has not previously been reported in GIMT; indeed, our study suggests that the expression of RCAS1 is correlated with recurrence not only in carcinomas, but also in mesenchymal tumors.